Mary Azer
Impact in
-
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
-
- Melanoma and MAPK Pathways
Papers in
-
- Melanoma and MAPK Pathways 6
- Oncology 7
- Cancer Immunotherapy and Biomarkers 3
- Cutaneous Melanoma Detection and Management 2
- HER2/EGFR in Cancer Research 2
- CAR-T cell therapy research 2
- Co-authors
- Georgina V. Long (6 shared papers)Richard Kefford (6 shared papers)Lauren E. Haydu (6 shared papers)Alexander M. Menzies (6 shared papers)Arthur Clements (2 shared papers)Peter J. Carr (1 shared paper)Matteo S. Carlino (1 shared paper)Oliver Klein (2 shared papers)
- Journals
- Journal of Clinical Oncology (4 papers)Cancer (2 papers)Melanoma Research (1 paper)Journal of Palliative Medicine (1 paper)PLoS ONE (1 paper)
- Partner nations
- AustraliaUnited StatesBrazil
In The Last Decade
Mary Azer
11 papers receiving 235 citations
Peers
Comparison fields: 5 of 53
- Oncology 108
- Molecular Biology 146
- Computational Theory and Mathematics 27
- Pulmonary and Respiratory Medicine 37
- Cancer Research 10
Countries citing papers authored by Mary Azer
This map shows the geographic impact of Mary Azer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Azer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Azer more than expected).
Fields of papers citing papers by Mary Azer
This network shows the impact of papers produced by Mary Azer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Azer. The network helps show where Mary Azer may publish in the future.
Co-authors
The 25 scholars most cited alongside Mary Azer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 72 | |
| 2 | 2014 | 56 | |
| 3 | 2013 | 32 | |
| 4 | 2014 | 31 | |
| 5 | 2008 | 18 | |
| 6 | 2013 | 9 | |
| 7 | 2018 | 7 | |
| 8 | 2012 | 3 | |
| 9 | 2022 | 3 | |
| 10 | 2024 | 3 | |
| 11 | 2023 | 2 | |
| 12 | Incidence and Management of Immune-Related Adverse Events at a Regional Hospital - A Review of 4 Years of Immunotherapy | 2017 | 1 |
| 13 | 2024 | 0 | |
| 14 | 2022 | 0 |
About Mary Azer
Mary Azer is a scholar working on Molecular Biology, Oncology, Organic Chemistry, Dermatology and Epidemiology, having authored 14 papers that have together received 237 indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (6 papers), Cancer Immunotherapy and Biomarkers (3 papers), Click Chemistry and Applications (2 papers), Cutaneous Melanoma Detection and Management (2 papers), Nonmelanoma Skin Cancer Studies (2 papers), HER2/EGFR in Cancer Research (2 papers), CAR-T cell therapy research (2 papers) and Pharmacogenetics and Drug Metabolism (1 paper). The work is most often cited by research in Oncology (108 citations), Molecular Biology (146 citations), Computational Theory and Mathematics (27 citations), Pulmonary and Respiratory Medicine (37 citations) and Cancer Research (10 citations). Mary Azer has collaborated with scholars based in Australia, United States and Brazil. Frequent co-authors include Georgina V. Long, Richard Kefford, Lauren E. Haydu, Alexander M. Menzies, Arthur Clements, Peter J. Carr, Matteo S. Carlino, Oliver Klein, Matthew Chan and Alexander Guminski. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Melanoma Research, Journal of Palliative Medicine and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.